Regeneration and Repair of Myelinated Fibers in Sural-Nerve Biopsy Specimens from Patients with Diabetic Neuropathy Treated with Sorbinil

New England Journal of Medicine

Volumn 319, Issue 9, 1988, Pages 548-555

  Sima, Anders A F ^a   Bril, Vera ^b   Nathaniel, Virgil ^a   McEwen, Thomas Aj ^a   Brown, Morton B ^c   Lattimer, Sarah A ^c   Greene, Douglas A ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORBINIL;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MYELINATED NERVE; NERVE REGENERATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURAL NERVE; ULTRASTRUCTURE;

EID: 0023748415     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198809013190905     Document Type: Article

References (65)

1. Johnson PC, Doll SC, Cromey DW. Pathogenesis of diabetic neuropathy. Ann Neurol 1986; 19: 450–7.
2. Sima AAF. Can the BB-rat help to unravel diabetic neuropathy? Neuropathol Appl Neurobiol 1985; 11: 253–64.
3. Melton LJ, Dyck PJ. Epidemiology. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr, eds. Diabetic neuropathy. Philadelphia: W.B. Saunders, 1987:27–35.
4. Greene DA, Lattimer SA, Ulbrecht J, Carroll P. Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 1985; 8: 290–9.
5. Winegrad AI, Simmons DA, Martin DB. Has one diabetic complication been explained? N Engl J Med 1983; 308: 152–4.
6. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium–potassium–ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599–606.
7. Brismar T, Sima AAF, Greene DA. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 1987; 21: 504–7.
8. Winegrad AI. Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987; 36: 396–406.
9. Dyck PJ, Karnes JL, O'Brien P, Okazaki H, Lais A, Engelstad J. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol 1986; 19: 440–9.
10. Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986; 19: 425–39.
11. Yasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 1987; 37: 20–8.
12. Greene DA, Gregersen G, Zimmerman BR. Metabolic control. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr, eds. Diabetic neuropathy. Philadelphia: W.B. Saunders, 1987:177–94.
13. Dvornik D, Porte D. Aldose reductase inhibition: an approach to the prevention of diabetic complications. New York: McGraw-Hill, 1987.
14. Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983; 308: 119–25.
15. Fagius J, Brattberg A, Jameson S, Beme C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985; 28: 323–9.
16. Mayer JH, Tomlinson DR. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 1983; 25: 433–8.
17. Yue DK, Hanwell MA, Satchell PM, Turtle JR. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 1982; 31: 789–94.
18. Jaspan J, Maselli R, Herold K, Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 1983; 2: 758–62.
19. Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983; 32: 938–42.
20. Lewin IG, O'Brien IAD, Morgan MH, Corrall RJM. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia 1984; 26: 445–8.
21. Lehtinen JM, Hyvönen SK, Uusitupa M, Puhakainen E, Halonen T, Kilpeläinen H. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiologic parameters of diabetic neuropathy. J Neurol 1986; 233: 174–7.
22. Christensen JEJ, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (Sorbinil®) on diabetic neuropathy and neural function of the retina: a double-blind study. Acta Neurol Scand 1985; 71: 164–7.
23. Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy — a clinical and neurophysiological study. J Neurol Neurosurg Psychiatry 1981; 44: 991–1001.
24. Handelsman DJ, Turtle JR. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 1981; 30: 459–64.
25. Dyck PJ, Karnes J, O'Brien PC. Diagnosis, staging and classification of diabetic neuropathy and associations with other complications. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr, eds. Diabetic neuropathy. Philadelphia: W.B. Saunders, 1987:36–44.
26. Sima AAF, Nathaniel V, Bril V, McEwen TAJ, Greene DA. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 1988; 81: 349–64.
27. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039–57.
28. Arezzo JC, Schaumburg HH, Petersen CA. Rapid screening for peripheral neuropathy: a field study with the Optacon. Neurology 1983; 33: 626–9.
29. Arezzo JC, Schaumburg HH, Laudadio C. Thermal sensitivity tester: device for quantitative assessment of thermal sense in diabetic neuropathy. Diabetes 1986; 35: 590–2.
30. Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA. Polyol pathway activity and myo-inositol metabolism: a suggested relationship in the pathogenesis of diabetic neuropathy. Diabetes 1983; 32: 988–92.
31. Sima AAF, Bouchier M, Christensen H. Axonal atrophy in sensory nerves of the diabetic BB-Wistar rat: a possible early correlate of human diabetic neuropathy. Ann Neurol 1983; 13: 262–72.
32. Dyck PJ, Karnes J, Lais A, Lofgren EP, Stevens JC. Pathologic alterations of the peripheral nervous system of humans. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, eds. Peripheral neuropathy. 2nd ed. Vol. 1. Philadelphia: W.B. Saunders, 1984:760–870.
33. Peterson MJ, Sarges R, Aldinger CE, MacDonald DP. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism 1979; 28: Suppl 1: 456–61.
34. Martyn CN, Matthews DM, Popp-Snijders C, Tucker J, Ewing DJ. Clarke BF. Effects of sorbinil treatment on erythrocytes and platelets of persons with diabetes. Diabetes Care 1986; 9: 36–9.
35. Pryce TD. On diabetic neuritis with a clinical and pathologic description of diabetic pseudo-tabes. Brain 1893; 16: 416–24.
36. Behse F, Buchtal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977; 40: 1072–82.
37. Bischoff A. Ultrastructural pathology of peripheral nervous system in early diabetes. In: Camerini-Dávalos RA. Cole HS, eds. Vascular and neurological changes in early diabetes. New York: Academic Press, 1973:441–9.
38. Reske-Nielsen E, Lundbæeck K. Pathological changes in the central and peripheral nervous system of young long-term diabetics. II. The spinal cord and peripheral nerves. Diabetologia 1968; 4: 34–43.
39. Said G, Slama G, Selva J. Progressive centripetal degeneration of axons in small fiber diabetic polyneuropathy. Brain 1983; 106: 791–807.
40. Sima AAF. Peripheral neuropathy in the spontaneously diabetic BB-Wistarrat: an ultrastructurai study. Acta Neuropathol (Berl) 1980; 51: 223–7.
41. Thomas PK, Lascelles RG. Schwann-cell abnormalities in diabetic neuropathy. Lancet 1965; 1: 1355–7.
42. Thomas The pathology of diabetic neuropathy. Q J Med 1966; 35: 489–509.
43. Chopra JS, Fannin T. Pathology of diabetic neuropathy. J Pathol 1971; 104: 175–84.
44. Chopra JS, Hurwitz LJ, Montgomery DAD. The pathogenesis of sural nerve changes in diabetes mellitus. Brain 1969; 92: 391–418.
45. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590–6.
46. Fagerberg S-E. Diabetic neuropathy: a clinical and histological study on the significance of vascular affections. Acta Med Scand [Suppl] 1959; 345: 1–97.
47. Vracko R. A comparison of the microvascular lesions in diabetes mellitus with those of normal aging. J Am Geriatr Soc 1982; 30: 201–5.
48. Williams E, Timperley WR, Ward JD, Duckworth T. Electron microscopical studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 1980; 33: 462–70.
49. Woltman HW, Wilder RM. Diabetes mellitus: pathologic changes in the spinal cord and peripheral nerves. Arch Intern Med 1929; 44: 576–603.
50. Olsson Y, Säve-Söderbergh J, Sourander P, Angervall L. A patho-anatomical study of the central and peripheral nervous system in diabetes of early onset and long duration. Path Europ 1968; 3: 62–79.
51. Chakrabarti S, Sima AAF, Nakajima T, Yagihashi S, Greene DA. Aldose reductase in the BB rat: isolation, immunological identification and localization in the retina and peripheral nerve. Diabetologia 1987; 30: 244–51.
52. Brismar T, Sima AAF. Changes in nodal function in nerve fibers of the spontaneously diabetic BB-Wistar rat; potential clamp analysis. Acta Physiol Scand 1981; 113: 499–506.
53. Greene DA, Mackway AM. Decreased myo-inositol content and Na+K+-ATPase activity in the superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition. Diabetes 1986; 35: 1106–8.
54. Green RJ, King RHM, Thomas PK, Baron DN. Sodium-potassium-ATPase activity in the dorsal root ganglia of rats with streptozotocin-induced diabetes. Diabetologia 1985; 28: 104–7.
55. Yorek MA, Dunlap JA, Ginsberg BH. myo-Inositol metabolism in 41A3 neuroblastoma cells: effects of high glucose and sorbitol levels. J Neurochem 1987; 48: 53–61.
56. Ishii DN, Recio-Pinto E, Spinelli W, Mill JF, Sonnenfeld KH. Neurite formation modulated by nerve growth factor, insulin, and tumor promoter receptors. Int J Neurosci 1985; 26: 109–27.
57. Mayer JH, Tomlinson DR. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 1983; 25: 433–8.
58. Low PA, Tuck RR, Takeuchi M. Nerve microenvironment in diabetic neuropathy. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D Jr. eds. Diabetic neuropathy. Philadelphia: W.B. Saunders. 1987:266–78.
59. Newrick PG, Wilson AJ, Jakubowski J, Boulton AJM, Ward JD. Sural nerve oxygen tension in diabetes. Br Med J 1986; 293: 1053–4.
60. Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984; 107: 935–50.
61. Williamson JR, Rowold E, Chang K, et al. Sex steroid dependency of diabetes-induced changes in polyol metabolism, vascular permeability, and collagen cross-linking. Diabetes 1986; 35: 20–7.
62. Morrison AD. Aortic smooth muscle metabolism: effect of polyol pathway inhibition. Clin Res 1984; 32: 851A. abstract.
63. Larson RE, Morrison AD. Effects of insulin on endothelial cell myoinositol metabolism. Diabetes 1986; 35: Suppl 1: 12A. abstract.
64. Simmons DA, Kern EFO, Winegrad AI, Martin DB. Basal phosphatidylinositol turnover controls aortic Na+K+ATPase activity. J Clin Invest 1986; 77: 503–13.
65. Mulvany MJ. Vascular effects of altered sodium, potassium pump activity. Scand J Clin Lab Invest [Suppl] 1986; 180: 40–8.